Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial – The Lancet (link to abstract – $ for full-text)

Commentary: Dulaglutide Cuts Cardiovascular Risk in Type 2 Diabetes – NEJM Journal Watch (free)

During a median follow-up of 5.4 years, the primary outcome (a composite endpoint of non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular causes) occurred in 12.0% of participants in the dulaglutide group and in 13.4% of participants in the placebo group (incidence rate of 2.4 per 100 person-years vs 2.7 per 100 person-years in the placebo group).


Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer – Journal of the American College of Cardiology (link to abstract – $ for full-text)

“In patients with HER2-positive breast cancer treated with trastuzumab, both lisinopril and carvedilol prevented cardiotoxicity in patients receiving anthracyclines.”


Review: Menopausal Hormone Therapy

31 May, 2019 | 06:30h | UTC

Menopausal Hormone Therapy – JAMA (free for a limited period)

Podcast: Menopausal Hormone Therapy (free audio)


Tramadol for osteoarthritis – Cochrane Library (free)

Summary: Tramadol for osteoarthritis – Cochrane Library (free)

“tramadol alone or in combination with acetaminophen probably has no important benefit on mean pain or function in people with osteoarthritis, although slightly more people in the tramadol group report an important improvement”


Deprescribing in Older Adults with Cardiovascular Disease – Journal of the American College of Cardiology (free for a limited period)

Related: Position Statement: Reducing Inappropriate Medication Use & Polypharmacy (several articles and commentaries on the subject)


Related Commentary on Twitter


At $2.1 Million, New Gene Therapy Is The Most Expensive Drug Ever – NPR (free)

See also: No Miracle Drug Should Cost $2.1 Million – Bloomberg Opinion (free) AND This New Treatment Could Save the Lives of Babies. But It Costs $2.1 Million. – The New York Times (10 articles per month are free)

“The price set by the Swiss drugmaker Novartis may be the world’s highest for a single treatment — prompting renewed debate about how society will pay for gene-therapy breakthroughs.” (from the New York Times)


Chronic use of tramadol after acute pain episode: cohort study – The BMJ (free)

Commentaries: Risk of Prolonged Use With Tramadol vs Other Short Acting Opioids Examined – MPR (free) AND ‘There really is no safe opioid’: Study finds tramadol isn’t a less addictive painkiller – CBC (free)


Related Commentary on Twitter


Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials – Intensive Care Medicine (free)

“Vasopressin therapy in septic shock had no effect on 28-day mortality”


EASL Clinical Practice Guidelines: Drug-induced liver injury – Journal of Hepatology (free)

Related Review: Drug-induced liver injury: recent advances in diagnosis and risk assessment – Gut (free)


Related Commentary on Twitter


Use of vitamin D drops leading to kidney failure in a 54-year-old man – Canadian Medical Association Journal (free)

“Vitamin D toxicity is rare, but clinicians must be aware of the risks of vitamin D use to limit complications related to hypercalcemia”.


A Clinical Overview of Off-label Use of Gabapentinoid Drugs – JAMA Internal Medicine (free for a limited period)

Related Meta-Analysis: Anticonvulsants in the Treatment of Low Back Pain and Lumbar Radicular Pain (free study and commentaries)

“Clinicians who prescribe gabapentinoids off-label for pain should be aware of the limited evidence and should acknowledge to patients that potential benefits are uncertain for most off-label uses.”


Reexamining Recommendations for Treatment of Hypercholesterolemia in Older Adults – JAMA (free for a limited period)

“This Viewpoint discusses the 2018 ACC/AHA cholesterol management guideline recommendation to consider statin treatment in adults aged >75 years with LDL levels 70-189 mg/dL, arguing that trial evidence does not support it…”


FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic – U.S. Food & Drug Administration (free)

Commentaries: A ketamine-like drug is the first new antidepressant to get FDA approval in years: But it’s also controversial. – Vox (free) AND FDA Approves Intranasal Esketamine as Adjunctive Treatment for Depression – NEJM Journal Watch (free)

“But while some patient and doctor groups are hailing the approval, others aren’t so sure there’s enough evidence to justify it. That’s because the benefits of ketamine and esketamine aren’t yet well-understood. According to the FDA, the drug has only been studied in four clinical trials, three of them lasting just four weeks. And the results were pretty mixed.” (from Vox)


Related Commentary on Twitter


Long-Term Risk of Heart Failure in Breast Cancer Patients After Adjuvant Chemotherapy With or Without Trastuzumab – JACC: Heart Failure (link to abstract – $ for full-text) (via @md_arianemacedo)

Commentary: Long-Term Risk of Heart Failure After Chemotherapy With Trastuzumab – American College of Cardiology (free)

“Trastuzumab treatment is associated with a 2-fold increased risk of late HF compared with chemotherapy treatment alone.”


Deprescribing benzodiazepine receptor agonists taken for insomnia: a review and key messages from practice guidelines – Polish Archives of Internal Medicine (free PDF)

Related: Guideline: Deprescribing Benzodiazepines (free guideline and resources) AND Position Statement: Reducing Inappropriate Medication Use & Polypharmacy (several articles and commentaries on the subject)



A practical guide for pharmacists to successfully implement penicillin allergy skin testing – American Journal of Health-System Pharmacy (free)

“Less than 10% of patients labeled as having a penicillin allergy are confirmed as present upon skin testing. This labeling results in use of alternative antibiotics and thus unwanted adverse consequences including potentiated antimicrobial resistance, increased costs, and worse clinical outcomes.”


International Consensus Guidelines for the Optimal Use of the Polymyxins – Pharmacotherapy (free)

Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).


American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults (free)

News Release: For older people, medications are common; AGS Beers Criteria aims to make them appropriate, too (free)

Commentary: AGS: Beers Criteria for Potentially Inappropriate Med Use in Older Adults Updated – MPR (free)


Related Commentary on Twitter


PSA’s Medicine Safety: Take Care – Pharmaceutical Society of Australia (free PDF)

News Release: Problems with medicines behind 250,000 hospital admissions annually (free)

“The report reveals that 250,000 Australians are hospitalised each year, with another 400,000 presenting to emergency departments, as a result of medication errors, inappropriate use, misadventure and interactions. At least half of this could have been prevented.”


Are Probiotics Money Down the Toilet? Or Worse? – JAMA (free for a limited period)

Related: Randomized Trials: Probiotics Ineffective Against Gastroenteritis (link to abstract and commentaries) AND Perspective: The Problem with Probiotics (free commentaries) AND Probiotics: Does the Evidence Match the Hype? (link to abstract and commentaries) AND Systematic Review: Harms Reporting in Trials with Probiotics (link to abstract and commentaries)


10 Myths About Frusemide

30 Jan, 2019 | 23:31h | UTC

10 myths about frusemide – Intensive Care Medicine (free)

Note: if the above link is paywalled, try this one


Implementation of a Health Plan Program for Switching From Analogue to Human Insulin and Glycemic Control Among Medicare Beneficiaries With Type 2 Diabetes – JAMA (link to abstract – $ for full-text)

Commentary: Medicare Patients with Type 2 Diabetes Safely Switched From Analog to Human Insulin, JAMA Study Finds – AJMC (free)

Related: Meta-Analysis: Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes (link to abstract and commentaries) AND Retrospective Observational Study: Basal Insulin Analogs vs NPH Insulin for Type 2 Diabetes (link to abstract and commentaries)

“Patients with type 2 diabetes (T2D) enrolled in a CareMore Health Medicare Part D plan switched from analog to human insulin without significant loss of glycemic control while saving millions for themselves and for the health plan.: (from AJMC)


Temporarily quadrupling the dose of inhaled steroid to prevent asthma exacerbations: FAST – Health Technology Assessment (free)


Related Commentary on Twitter


Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life – Cochrane Library (free)

Summary: Vitamin and mineral supplementation for preventing cognitive deterioration in cognitively healthy people in mid and late life – Cochrane Library (free)

Commentary: Preventing dementia: do vitamin and mineral supplements have a role? – Evidently Cochrane (free)


Related Commentary on Twitter


Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies – Osteoporosis International (link to abstract – $ for full-text)

Commentary: PPIs up risk for hip fracture in large meta-analysis – Univadis (free registration required)


Related Commentary on Twitter

ADA 2019 Standards of Medical Care in Diabetes (free supplement)

News Release: Patient-centered Care is the Focus and Priority of the 2019 Standards of Medical Care in Diabetes, Published Today by the American Diabetes Association (free)

Summary of Revisions: Standards of Medical Care in Diabetes—2019 (free)

See also: Standards of Medical Care in Diabetes—2019 Abridged for Primary Care Providers (free PDF)


Related Commentary on Twitter

Fluoroquinolones and the risk of aortopathy: A systematic review and meta-analysis – International Journal of Cardiology (free)

“…current fluoroquinolone use was significantly associated with increased risk of aortic aneurysm and dissection.”


Study: Trazodone Associated Risks

30 Nov, 2018 | 02:40h | UTC

Review: Cannabinoids for Chronic Pain

30 Nov, 2018 | 01:45h | UTC

Cannabinoids for Chronic Pain – Therapeutics Initiative (free)

Related: Meta-Analysis: Cannabinoids for the Treatment of Chronic Noncancer Pain Conditions (free) AND Guideline for Prescribing Medical Cannabinoids in Primary Care (free article and commentary)

“At the present time we lack good evidence that any cannabis-derived product works for chronic pain”


Review: Opioids and Cardiac Arrhythmia

30 Nov, 2018 | 01:27h | UTC

Report: 2018 Access to Medicine Index

22 Nov, 2018 | 21:54h | UTC

Antipsychotic drug use and pneumonia: Systematic review and meta-analysis – Journal of Psychopharmacology (link to abstract – $ for full-text)

Commentary: Antipsychotics May Increase Risk of Pneumonia, Meta-Analysis Suggests – Psychiatric News Alert (free)

“Although antipsychotic use was associated with a higher risk of pneumonia, the researchers stopped short of claiming causality, citing a lack of data from randomized, controlled trials and a failure of observational studies to control for relevant confounders like tobacco use and weight.” (from Psychiatric News Alert)


Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD) – Cochrane Library (free)

Summary: Preventative antibiotic therapy for people with COPD – Cochrane Library (free)

“Use of continuous and intermittent prophylactic antibiotics results in a clinically significant benefit in reducing exacerbations in COPD patients.”